|}
<br>
===Business linesKey Financials===The company operates under the following business lines: [[Image:Business_lines.PNG|centre]]
==Financial overview==
{|border="2" cellspacing="0" cellpadding="4" width="71%" align="center"
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Olympus Corporation'''</font>
|}
<br>
===Revenue Distribution===
{|align="center"
|<gflash>1100 825 http://dolcera.com/upload/files/Revenue_Metrics.swf</gflash>
Source: SEC fillings
==Business Overview== ===Business lines===The company operates under the following business lines: [[Image:Business_lines.PNG|centre]] ===Employee Distribution===
<br>
===Organisation Structure===
[[Image:OrgChart_Oympus.png|centre]]
<br>
==Medical SystemsBusiness==
The Medical Systems Business covers gastrointestinal endoscopes, surgical endoscopes, endotherapy devices, endoscopic ultrasound systems and medical information systems.
<br>
==EndoscopesBusiness==
* The Exera 2, the previous entry in the Exera series, used NBI technology to enable full-color endoscopy, allowing doctors to more easily recognize affected areas in their patients. This product thus addressed doctors’ needs in the area of visibility, and sales grew worldwide.
==Gastrointestinal EndoscopyEndoscopes Business==
With an approximately 70% global market share for gastrointestinal endoscopes and an established position at the medical vanguard, Olympus maintains its passion for advancing technologies in response to doctors' needs